Results 21 to 30 of about 16,284 (167)

Factor VII deficiency-related recurrent hemarthrosis in a female child – When to suspect?

Iraqi Journal of Hematology, 2021
Recurrent hemarthrosis is a common entity in children. Although recurrent hemarthrosis most often associated with hemophilia (VIII or IX deficiency), but rarely it can be associated with factor VII deficiency (FVIID).
Siyaram Didel, Abhishek H. L. Purohit, Deepthi Krishna, Varuna Vyas, Kuldeep Singh   +4 more
doaj   +1 more source

Low-dose recombinant factor VIIa for massive bleeding

Swiss Medical Weekly, 2011
QUESTIONS UNDER STUDY: recombinant activated factor VII (rFVIIa) is used off-label for massive bleeding. There is no convincing evidence of the benefits of this practice and the minimal effective dose is unknown.
A Mordasini, M Luginbühl, B Regli, HP Kohler, D Inderbitzin, B Lämmle, L Alberio   +6 more
doaj   +1 more source

Thrombin generation during cardiopulmonary bypass: the possible role of retransfusion of blood aspirated from the surgical field

Thrombosis Journal, 2003
Background In spite of using heparin-coated extracorporeal circuits, cardiopulmonary bypass (CPB) is still associated with an extensive thrombin generation, which is only partially suppressed by the use of high dosages of heparin.
de Jong Dick S, Caberg Nicole EH, Lindhout Theo, Weerwind Patrick W   +3 more
doaj   +1 more source

A thrombophilic allele of clotting Factor VII/VIIa promoting recurrent pulmonary emboli, clinical details, and a structural model of the altered protein: a case report

Journal of Medical Case Reports, 2023
Background The clotting or hemostasis system is a meticulously regulated set of enzymatic reactions that occur in the blood and culminate in formation of a fibrin clot.
Kenneth Newman, Fevzi Daldal, Andrew Dancis   +2 more
doaj   +1 more source

Camelid‐derived single‐chain antibodies in hemostasis: Mechanistic, diagnostic, and therapeutic applications

Research and Practice in Thrombosis and Haemostasis, 2020
Hemostasis is a complex process involving the concerted action of molecular and vascular components. Its basic understanding as well as diagnostic and therapeutic aspects have greatly benefited from the use of monoclonal antibodies.
Ivan Peyron, Claire Kizlik‐Masson, Marie‐Daniéla Dubois, Sénadé Atsou, Stephen Ferrière, Cécile V. Denis, Peter J. Lenting, Caterina Casari, Olivier D. Christophe   +8 more
doaj   +1 more source

Adiponectin alleviate blood hypercoagulability via inhibiting endothelial cell apoptosis induced by oxidative stress in septic rats [PDF]

Iranian Journal of Basic Medical Sciences, 2018
Objective(s): The purpose of this study was to detect the protective effects of adiponectin on coagulation dysfunction and its mechanism in sepsis of rats.Materials and Methods: The experimental samples were composed of sham group,   model group that was
Yun Hou, Xi-Feng Wang, Zhi-Qiang Lang, Wei Zhao, Yinchuan Jin, Hong-Qin Zhang, Lian-Shuang Zhang   +6 more
doaj   +1 more source

AryoSeven RT (Coagulation factor VIIa, recombinant) safety and efficacy study among congenial factor VII deficient patients in Iraq

Iraqi Journal of Hematology, 2022
BACKGROUND: Recombinant activated factor VII (FVII) is a product onetime evolved to stop bleeding occurring in hemophilia A and B patients with inhibitor, congenital FVII deficiency, Glanzmann disease, and in life-threatening bleeding.
Nidal Karim Al-Rahal, Ahmed Shemran Alwataify, Safa Mohammed Shawkat, Israa Almusawi, Azeezah Mohammed Mohsin   +4 more
doaj   +1 more source

Control of disseminated intravascular coagulation in Klippel-Trenaunay-Weber syndrome using enoxaparin and recombinant activated factor VIIa: a case report

Journal of Medical Case Reports, 2010
Introduction Vascular malformation is associated with coagulopathies, especially when hemostasis is challenged. Case presentation We present the case of an 11-year-old Hispanic girl with Klippel-Trenaunay-Weber syndrome that developed disseminated ...
Kecskes Susan, Hast Howard, Schmidt Mary, Beier Ulf H, Valentino Leonard A   +4 more
doaj   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Large‐scale bidirectional arrayed genetic screens identify OXR1 and EMC4 as modifiers of αSynuclein aggregation

FEBS Open Bio, EarlyView.
Activation of the mitochondrial protein OXR1 increases pSyn129 αSynuclein aggregation by lowering ATP levels and altering mitochondrial membrane potential, particularly in response to MSA‐derived fibrils. In contrast, ablation of the ER protein EMC4 enhances autophagic flux and lysosomal clearance, broadly reducing α‐synuclein aggregates.
Sandesh Neupane, Lea Nikolić, Lorenzo Maraio, Thomas Goiran, Nathan Karpilovsky, Stefano Sellitto, Vangelis Bouris, Jiang‐An Yin, Ronald Melki, Edward A Fon, Adriano Aguzzi, Elena De Cecco   +11 more
wiley   +1 more source